Verma Deepti, Chandra Jagdish, Kumar Praveen, Shukla Shailaja, Sengupta Shantanu
Department of Pediatrics, Kalawati Saran Children's Hospital (associated with Lady Hardinge Medical College), New Delhi, India.
Department of Pathology, Lady Hardinge Medical College, New Delhi, India.
Pediatr Blood Cancer. 2017 Dec;64(12). doi: 10.1002/pbc.26698. Epub 2017 Jul 1.
To demonstrate the efficacy of oral methylcobalamin in treating vitamin B12 (vitB12) deficiency anemia, our prospective observational study enrolled 28 children with both macrocytic anemia and low holotranscobalamin (HoloTC) levels. Their hematological and biochemical parameters pre- and posttreatment at 1 month were compared. Hemoglobin showed mean increase of 2.89 g/dl (P < 0.001), rising above 10 g/dl in 24 patients (85.7%). Reticulocytes peaked at 1 week. Mean fall in mean corpuscular volume of 24.83 fl (P < 0.001) and mean improvement in platelets of 122,100/μl (P = 0.001) were noted, and mean rise in HoloTC and vitB12 were 111.36 pmol/l (P < 0.001) and 918.34 pg/ml (P < 0.001), respectively. Thus, initial responses to oral methylcobalamin in children with vitB12 deficiency anemia were adequate.
为证明口服甲钴胺治疗维生素B12（vitB12）缺乏性贫血的疗效，我们的前瞻性观察性研究纳入了28名患有大细胞性贫血且全转钴胺素（HoloTC）水平较低的儿童。比较了他们治疗前和治疗1个月后的血液学和生化参数。血红蛋白平均升高2.89 g/dl（P < 0.001），24名患者（85.7%）升至10 g/dl以上。网织红细胞在1周时达到峰值。观察到平均红细胞体积平均下降24.83 fl（P < 0.001），血小板平均改善122,100/μl（P = 0.001），HoloTC和vitB12平均升高分别为111.36 pmol/l（P < 0.001）和918.34 pg/ml（P < 0.001）。因此，vitB12缺乏性贫血儿童对口服甲钴胺的初始反应良好。
